Why Asia Is Becoming the Global Hub for Next-Gen Medicine

Back to Blog

Share this article:

Why Asia, Why Now?

Asia is fast emerging as a global leader in life sciences innovation due to significant public investment, a rapidly growing biotech ecosystem, and widespread adoption of advanced technologies.

According to Bain & Company, Asia-Pacific’s biotech sector has grown rapidly over the past five years, driven by government funding, venture capital interest, and robust infrastructure development.¹

Hand holding assorted capsules and supplements representing next-generation medicine in Asia.

Drug Discovery: Smarter, Faster, More Localized

AI in Target Discovery & Screening
Asian biotech companies are using AI to accelerate the early stages of drug development, particularly in target identification and compound screening. Kalbe Digital Lab (Indonesia) has integrated AI and high-throughput screening into their R&D process to boost biomarker discovery and reduce candidate selection time.²

Mechanistic Disease Modeling
Researchers across Asia are now focusing on mechanism-based modeling using multi-omics to understand complex diseases like cancer, neurological disorders, and rare conditions. The Experimental Drug Development Centre (EDDC) Singapore has emphasized partnerships with academic hospitals to build translational pipelines using genomics and disease models.³

Automation & Assay Customization

Automation and AI-driven customization of disease assays are enabling research hubs in Asia to scale drug discovery more efficiently, particularly for neurological and cardiovascular conditions. In Japan and Singapore, laboratories are integrating high-throughput screening systems with custom assay designs—streamlining workflows, improving precision, and accelerating timelines in targeted drug discovery.⁴

Nucleic Acids: Redefining Therapies at the Molecular Level

Aptamers & DNA Recognition
Asia-based research teams are advancing aptamer technology to improve disease detection and precision targeting in diagnostics and therapy. Weihong Tan’s lab in China developed Cell-SELEX-based DNA aptamers that selectively bind disease-specific cells, enabling early tumor identification and drug delivery.⁵

siRNA Delivery Technologies
Clinical-stage siRNA therapies are gaining traction in Asia thanks to breakthroughs in delivery systems that improve tissue specificity and minimize side effects. Sirnaomics (Hong Kong) has launched clinical trials using peptide nanoparticle and GalNAc platforms to treat squamous cell carcinoma and thrombotic disorders.⁶

Minimal DNA Vectors
Minimal, non-viral DNA vector technologies are emerging across Asia to address the limitations of viral vectors, including manufacturing complexity and cold-chain dependence. Singapore’s SPRING DNA™ platform exemplifies this innovation—designed as a stable, minimal vector requiring no cold chain, with the potential for multi-month gene expression from a single dose. Similar non-viral DNA nanovector approaches have demonstrated persistent episomal replication and sustained transgene expression in preclinical models.⁷

Precision Medicine: Data, Diversity & Delivery

National Bio Big Data Projects
Governments in Asia are building large-scale biobanks to integrate genomics with healthcare delivery and policymaking. South Korea’s National Institute of Health is leading a bio big data initiative with over one million participants to fuel research into chronic diseases and rare conditions.⁸

Genomics in Pediatric Oncology
Asian medical institutions are increasingly integrating precision medicine into real-world pediatric oncology. At Universiti Kebangsaan Malaysia (UKM), next-generation sequencing (NGS) tools—including whole-genome and targeted RNA sequencing—have been employed on Malaysian pediatric acute myeloid leukemia (AML) patients to delineate mutational landscapes across diagnosis, remission, and relapse stages, significantly enhancing understanding of molecular disease dynamics.⁹

AI + Wearables for Daily Health Monitoring
The convergence of wearable technology and multi-omics microsampling is transforming personalized health monitoring across Asia. At NTU Singapore, researchers have pioneered the use of 10 µL finger‑prick blood microsamples combined with continuous physiological data from wearable sensors to capture high‑precision, dynamic profiles of inflammatory and metabolic responses over time. This innovative approach enables frequent, minimally invasive health sampling—supporting real‑time insights tailored to the individual.¹⁰

Want to Go Deeper?

If you’re in research, clinical development, or biotech innovation, the Discovery & Development Summit Asia 2025 (September 9–10, Singapore) will bring together these leading voices and real-world case studies.

Tracks include: